Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Interim results of a post-marketing surveillance study

Expert Opinion on Pharmacotherapy
Yasuo TerauchiHaruko Sugamori

Abstract

To determine the incidence of adverse drug reactions (ADRs) associated with ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus. We report interim results of a postmarketing surveillance survey. Japanese physicians recorded ADRs in elderly patients (≥ 65 years old) who were first prescribed with ipragliflozin within 3 months of its launch (April 2014). Incidence of ADRs within 1 year of starting treatment with ipragliflozin. 898 ADRs occurred in 721/7,170 patients (10.06%). Skin complication-, volume depletion-, genital infection-, polyuria/pollakiuria-, urinary tract infection-, and hypoglycemia-related ADRs occurred in 2.23%, 1.90%, 1.45%, 1.32%, 0.77%, and 0.32%, respectively. ADRs were classified as serious in 44 (0.61%) patients. Half of the ADRs occurred within 30 days of starting treatment. There were no cases of Stevens-Johnson syndrome or toxic epidermal necrolysis. Most (92.1%) of the ADRs resolved or improved. Glycated hemoglobin, fasting blood glucose, body weight, and systolic blood pressure decreased by 0.6% (baseline 7.8%), 22.7 mg/dL (baseline 163.0 mg/dL), 2.3 kg (baseline 67.4 kg), and 3.1 mmHg (baseline 133.2 mmHg), respectively, from baseline to treatment discontinuation/last visit. Ipra...Continue Reading

References

Feb 14, 2009·The Journal of Nutrition, Health & Aging·J M G A ScholsM G M Olde Rikkert
Jun 29, 2013·Journal of Diabetes and Its Complications·Kristina M JohnssonJames F List
Jul 16, 2013·Journal of Diabetes and Its Complications·Kristina M JohnssonJames F List
Sep 13, 2013·Annals of Internal Medicine·Despoina VasilakouApostolos Tsapas
Apr 16, 2014·Diabetes Research and Clinical Practice·Trisha DunningStephen Colagiuri
Dec 20, 2014·The Lancet. Diabetes & Endocrinology·Simeon I TaylorKristina I Rother
Sep 13, 2015·Biochemical Pharmacology·I DardiS A Jabbour
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Sep 30, 2015·Journal of Diabetes Investigation·Hadrien CharvatManami Inoue

❮ Previous
Next ❯

Citations

Sep 7, 2016·Expert Opinion on Pharmacotherapy·Hiroyuki ItoMariko Abe
Dec 20, 2019·Therapeutic Advances in Cardiovascular Disease·Takahiro KambaraMasayoshi Ajioka
Mar 18, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Ichiro NakamuraSatoshi Uno

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

© 2022 Meta ULC. All rights reserved